The development of new methods for the prevention and treatment of chronic heart failure and its control is an urgent medical and social problem. In this regard, using of new biological markers of the disease may be useful for early diagnosis of the disease, predict a clinical course, monitor the effects of pharmacotherapy (personalized medicine) and play an important role in stratifying the patient's risk. In 2013, according to the recommendation of the American Heart Association, a galectin-3 was introduced into the pool of such biomarkers for prevention and treatment of chronic heart failure. Objective: to improve prediction of the course and effectiveness of the therapy for hypertension and chronic heart failure as the hypertension complication in men 40-60 years old by applying the level of galectin-3 as a biomarker. There were observed the men 40-60 years old with hypertension and chronic heart failure for the concentration of galectin-3. Also, there were observed subjects without cardiovascular pathology (n=79), the men with hypertonic disease with myocardial hypertension (n=62) and the men with chronic heart failure II-III functional class of NYHA (n=50) for the indicators of central and systemic hemodynamics. The level of galectin-3 was determined by immunoassay analysis on the equipment "Stat Fact 300". Structural and functional parameters of myocardium were assessed by an ultrasound method using the equipment "RADMIR ULTIMARA". Data statistical analysis was performed on a personal computer using standard statistical package "Statistica 10.0". All data is presented in the form of average (M) and standard deviation (± σ). It has been established that the concentration of galectin-3 significantly decreases against the background of treatment. The level of galectin-3 in the patients with the II stage of hypertonic disease with good treatment effect was close to normal values compared to those with moderate treatment effect. In terms of patients with hypertension III stage, the level of galectin-3 also decreased, indicating the possibility of therapy monitoring using this biomarker. The mathematical model of the galectin-3 influencing factors also has been determined in patients with hypertension. The boundary level of the galectin-3 has been calculated, it is counted 46.51 pg/ml. It might be assumed a moderate effect of the treatment of hypertensive patients and chronic heart failure in males.

Pericarditis with or without pericardial effusion, which occurs as a result of pericardial damage, is a postcardiac trauma syndrome. Most reported cases of post-traumatic pericarditis document a history of direct trauma to the chest, such as chest trauma from a steering wheel, which was observed during car accidents or caused by mechanical damage to the chest of various genesis. Many methods of treatment of inflammatory diseases of the pericardium have been proposed – from palliative to radical. The most common among them are percutaneous pericardial puncture, extrapleural pericardiotomy, or fenestration, partial or subtotal resection of the pericardium. The choice of surgical tactics largely depends on the specialist who performs it and the clinic where this treatment takes place, and not on the specific situation. Inflammatory pericardial syndrome can be established in the presence of at least 2 of the following 4 criteria: pericardial chest pain; pericardial murmur; the appearance of a new widespread convex elevation of the ST segment or depression of the PR segment (in several leads excluding aVR and sometimes V1) on the electrocardiogram; pericardial effusion (new, or an increase in the severity of the existing one according to echocardiography and radiography of the chest cavity). Additional signs include: an increase in the concentration of inflammatory markers (C-reactive protein, erythrocyte sedimentation rate, leukocytosis) and markers of myocardial damage (CFC, troponin I); signs of the inflammatory process in the pericardium during imaging methods (computed tomography, magnetic resonance imaging).

The concentrations of galectin-3 and BNP, central and systemic hemodynamics, structural and functional heart parameters in male carriers of polymorphic AT1R genes without cardiovascular pathology (n = 79) living in Podillya region were studied. Genotyping of the AT1R gene was carried out using a polymerase chain reaction. The level of galectin-3 and BNP was determined by the method of enzyme immunoassay. It was found that the A1166A genotype dominated in practically healthy men of Podilly region. Nevertheless, the level of galectin-3 and BNP in the studied population did not significantly depend on the carriage of a specific variant of the AT1R gene.

Essential hypertension and its common complication - chronic heart failure, is one of the most significant medical, economic and social problems in the XXI century. At the same time, this pathology is 30-40% genetically predisposed. One of significant pathogenic factors is the inheritance of definite variants of genes, coding the receptors to angiotensin II type 1. For this reason, the effective and inexpensive researches for screening of the mentioned genetic phenomenon are being carried out. Objective: to improve the screening diagnostic methods for carriers of polymorphic genes of angiotensin II type 1 receptors with essential hypertension and essential hypertension complicated by chronic heart failure. There were studied dermatoglyphic prints of men 40-60 years, who are carriers of polymorphic gene variants of angiotensin II type 1 receptor with no cardiovascular diseases (n=79), male patients with essential hypertension and hypertrophy of the myocardium (stage II), II-III stages (n=62) and essential hypertension (n=50) complicated by chronic heart failure, residents of Podillya region of Ukraine. Genotyping of the gene of angiotensin II type 1 receptor was performed using polymerase chain reaction. All patients included in the control group and those with essential hypertension underwent dermatoglyphic examination of fingers on both hands using modern portable rolling scanner Futronic FS50 (Korea). Interpretation and decoding of dermatoglyphic prints was conducted by T. D. Gladkova’s method. Statistical analysis was done on personal computer using standard statistical package “STATISTICA 10.0”. The found ulnar loop was dominant dermatoglyphic print regardless of the presence or absence of essential hypertension and chronic heart failure in 40-60 year old men. Besides, positive correlation relationship was revealed between the inheritance gene of angiotensin II type 1 receptors and fingerprint patterns: the third finger on the left hand in males with no cardiovascular pathology (weak strength) and the second finger on the right hand in patients with essential hypertension (medium strength). In individuals with no cardiovascular diseases, carriers of genotype A1166A, prevalence of ulnar loop on the third finger of left hand is higher than in carriers of C allele gene of angiotensin II type 1 receptors. In males with essential hypertension, carriers of C allele, degree of incidence of the whorl on the second finger of right hand is significantly higher than in carriers of genotype А1166А, offering the possibility to determine the carriership of a particular gene of angiotensin II type 1 receptors. Carrying out dermatoglyphic examination in patients with an increase in blood pressure and determining the variant of carrier of the gene of the receptor to angiotensin II type 1 will make it possible to facilitate the selection of those individuals who in the future need to spend all the necessary amount of research to confirm the diagnosis of essential hypertension and the possible development of complications of the course of this cardiovascular disease.